Evaluating the utility of ZNF331 promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance)
Elizabeth S. NakasoneTyler J. ZemlaMing YuShe Yu LinFang-Shu OuKelly CarterFederico InnocentiLeonard SaltzWilliam M. GradyStacey A. Cohena Division of Oncology,University of Washington,Seattle,WA,USAb Translational Science and Therapeutics Division,Fred Hutchinson Cancer Center,Seattle,WA,USAc Alliance Statistics and Data Management Center,Mayo Clinic,Rochester,MN,USAd School of Life Sciences,Nantong University,Nantong,P.R. Chinae Division of Pharmacotherapy and Experimental Therapeutics,University of North Carolina at Chapel Hill,Chapel Hill,NC,USAf Department of Gastrointestinal Oncology,Memorial Sloan Kettering Cancer Center,New York,NY,USAg Division of Gastroenterology,University of Washington,Seattle,WA,USA
DOI: https://doi.org/10.1080/15592294.2024.2349980
2024-05-08
Epigenetics
Abstract:While epigenomic alterations are common in colorectal cancers (CRC), few epigenomic biomarkers that risk-stratify patients have been identified. We thus sought to determine the potential of ZNF331 promoter hypermethylation (m ZNF331 ) as a prognostic and predictive marker in colon cancer. We examined the association of m ZNF331 with clinicopathologic features, relapse, survival, and treatment efficacy in patients with stage III colon cancer treated within a randomized adjuvant chemotherapy trial (CALGB/Alliance89803). Residual tumour tissue was available for genomic DNA extraction and methylation analysis for 385 patients. ZNF331 promoter methylation status was determined by bisulphite conversion and fluorescence-based real-time polymerase chain reaction. Kaplan-Meier estimator and Cox proportional hazard models were used to assess the prognostic and predictive role of m ZNF331 in this well-annotated dataset, adjusting for clinicopathologic features and standard molecular markers. m ZNF331 was observed in 267/385 (69.4%) evaluable cases. Histopathologic features were largely similar between patients with m ZNF331 compared to unmethylated ZNF331 (unm ZNFF31 ). There was no significant difference in disease-free or overall survival between patients with m ZNF331 versus unm ZNF331 colon cancers, even when adjusting for clinicopathologic features and molecular marker status. Similarly, there was no difference in disease-free or overall survival across treatment arms when stratified by ZNF331 methylation status. While ZNF331 promoter hypermethylation is frequently observed in CRC, our current study of a small subset of patients with stage III colon cancer suggests limited applicability as a prognostic marker. Larger studies may provide more insight and clarity into the applicability of m ZNF331 as a prognostic and predictive marker.
biochemistry & molecular biology,genetics & heredity